174 related articles for article (PubMed ID: 23931274)
1. Viral RNA polymerase: a promising antiviral target for influenza A virus.
Shi F; Xie Y; Shi L; Xu W
Curr Med Chem; 2013; 20(31):3923-34. PubMed ID: 23931274
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis and treatment of influenza virus infection.
Kandel R; Hartshorn KL
BioDrugs; 2001; 15(5):303-23. PubMed ID: 11437694
[TBL] [Abstract][Full Text] [Related]
3. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development.
Zhang J; Hu Y; Musharrafieh R; Yin H; Wang J
Curr Med Chem; 2019; 26(13):2243-2263. PubMed ID: 29984646
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay.
Eichelberger MC; Hassantoufighi A; Wu M; Li M
Virol J; 2008 Sep; 5():109. PubMed ID: 18822145
[TBL] [Abstract][Full Text] [Related]
5. Influenza Virus: A Master Tactician in Innate Immune Evasion and Novel Therapeutic Interventions.
Hsu AC
Front Immunol; 2018; 9():743. PubMed ID: 29755452
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
7. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
8. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Byrn RA; Jones SM; Bennett HB; Bral C; Clark MP; Jacobs MD; Kwong AD; Ledeboer MW; Leeman JR; McNeil CF; Murcko MA; Nezami A; Perola E; Rijnbrand R; Saxena K; Tsai AW; Zhou Y; Charifson PS
Antimicrob Agents Chemother; 2015 Mar; 59(3):1569-82. PubMed ID: 25547360
[TBL] [Abstract][Full Text] [Related]
9. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK; Tsai CH; Shie JJ; Fang JM
Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
[TBL] [Abstract][Full Text] [Related]
10. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
11. Optimizing antiviral therapy for influenza: understanding the evidence.
Ison MG
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):417-25. PubMed ID: 25695406
[TBL] [Abstract][Full Text] [Related]
12. Strategies of development of antiviral agents directed against influenza virus replication.
Hsieh HP; Hsu JT
Curr Pharm Des; 2007; 13(34):3531-42. PubMed ID: 18220789
[TBL] [Abstract][Full Text] [Related]
13. [Present and future in development of new anti-influenza drugs].
Watanabe A
Nihon Rinsho; 2010 Sep; 68(9):1685-9. PubMed ID: 20845748
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus resistance to neuraminidase inhibitors.
Samson M; Pizzorno A; Abed Y; Boivin G
Antiviral Res; 2013 May; 98(2):174-85. PubMed ID: 23523943
[TBL] [Abstract][Full Text] [Related]
15. [Influenza virus RNA polymerase].
Toyoda T
Tanpakushitsu Kakusan Koso; 2007 Aug; 52(10 Suppl):1144-8. PubMed ID: 17824231
[No Abstract] [Full Text] [Related]
16. [Target of developing the new anti-influenza virus reagents].
Toyoda T
Nihon Rinsho; 2003 Nov; 61(11):1980-6. PubMed ID: 14619442
[TBL] [Abstract][Full Text] [Related]
17. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis.
Martinez-Gil L; Alamares-Sapuay JG; Ramana Reddy MV; Goff PH; Premkumar Reddy E; Palese P
Antiviral Res; 2013 Oct; 100(1):29-37. PubMed ID: 23891991
[TBL] [Abstract][Full Text] [Related]
18. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
[TBL] [Abstract][Full Text] [Related]
19. Emerging antiviral targets for influenza A virus.
Krug RM; Aramini JM
Trends Pharmacol Sci; 2009 Jun; 30(6):269-77. PubMed ID: 19428126
[TBL] [Abstract][Full Text] [Related]
20. Antivirals--current trends in fighting influenza.
Król E; Rychłowska M; Szewczyk B
Acta Biochim Pol; 2014; 61(3):495-504. PubMed ID: 25180220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
